Data and Safety Monitoring Board (DSMB) Process Streamlined in the Protocol; Could Accelerate Patient Enrollment and Treatment in European Trial…
Follows on Orphan Drug Status Granted by FDA Last Year, as Company Initiates Clinical Trial for Stargardt’s Disease MARLBOROUGH, Mass….
Patients for Phase 1/2 Trials Enrolled at UCLA MARLBOROUGH, Mass. – June 16, 2011 – Advanced Cell Technology, Inc. (“ACT”;…
Institutional Review Board (IRB) Approval for Phase I/II Clinical Trial for Dry AMD from Primary Teaching Hospital for Harvard Medical…
MARLBOROUGH, Mass. — March 24, 2014 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of…
Worcester, MA – Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC.OB) announced today that it has closed a private placement…
FDA Lifts Clinical Hold; Company to Commence a Phase I/II Clinical Trial at Multiple Centers MARLBOROUGH, MA – November 22,…
Stem cell research offers an ever-shifting battlefield, with vested interests and biologists squabbling over the political, ethical, and scientific merits…
MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, reported today that…
Worcester, MA, – Advanced Cell Technology, Inc. (ACT) today announced that it has successfully developed a method for producing primitive…